{
    "nct_id": "NCT00795730",
    "title": "An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects and Subjects With Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2021-08-17",
    "description_brief": "This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "NSA-789 (investigational oral small-molecule; Wyeth/Pfizer-sponsored; mechanism not publicly specified)"
    ],
    "placebo": [
        "Placebo (used as comparator in the trials)"
    ],
    "explanation_target": [
        "Reason: The provided trial title and registry records show NSA-789 is an orally administered, phase\u20111 investigational compound tested for safety, PK/PD in healthy volunteers and in subjects with Alzheimer disease \u2014 a setup typical for centrally active small molecules rather than biologic agents. \ue200cite\ue202turn1search5\ue202turn0search1\ue201",
        "Act (key details & searches): NSA-789 appears in multiple phase\u20111 trials (single\u2011 and multiple\u2011dose; healthy volunteers, schizophrenia, and Alzheimer disease) sponsored by Wyeth (now part of Pfizer), with endpoints of safety, pharmacokinetics and pharmacodynamics. A schizophrenia study tested effects on auditory P50 suppression (a sensory\u2011gating/cognitive biomarker). These registry entries do not name a molecular target or class for NSA\u2011789. \ue200cite\ue202turn0search1\ue202turn1search5\ue202turn0search6\ue201",
        "Act (mechanism search): A focused literature/registry search did not yield a definitive public description of NSA\u2011789\u2019s molecular target or chemical structure; no peer\u2011reviewed paper or company disclosure was found that specifies its receptor/enzyme target. The oral route and development program (schizophrenia, P50 biomarker, Alzheimer\u2019s safety/PK/PD) suggest a centrally acting small molecule aimed at improving cognitive/neuronal information\u2011processing rather than a biologic disease\u2011modifying agent. \ue200cite\ue202turn1search5\ue202turn0search1\ue201",
        "Inference supporting category: P50 auditory sensory\u2011gating deficits are commonly used to evaluate alpha\u20117 nicotinic acetylcholine receptor (\u03b17 nAChR) agonists/PAMs and other cognition\u2011directed agents in schizophrenia and related cognitive\u2011symptom research \u2014 this provides a plausible mechanistic hypothesis (cognitive\u2011enhancing, neuromodulatory action) for NSA\u2011789, but this is an inference because no direct evidence linking NSA\u2011789 to \u03b17 or any other specific target was found. \ue200cite\ue202turn2search0\ue202turn0search6\ue201",
        "Reflect: Given (a) oral, small\u2011molecule development in phase\u20111 trials, (b) testing in schizophrenia with P50 (a cognitive/sensory\u2011gating biomarker) and (c) a subsequent safety/PK/PD study in Alzheimer\u2019s subjects, the most consistent classification is 'Cognitive enhancer' (centrally acting agent intended to improve cognitive or information\u2011processing function). There is uncertainty because the sponsor did not publicly disclose the precise molecular target in accessible registries or publications; if you need definitive classification by mechanism (e.g., \u03b17 agonist vs. other), I can continue searching or attempt to contact sponsor records / patent filings. \ue200cite\ue202turn1search5\ue202turn0search6\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial describes NSA-789 as an orally administered investigational small molecule developed as a 'cognitive enhancer' with phase\u20111 studies in healthy volunteers, schizophrenia (P50 auditory gating), and Alzheimer disease \u2014 a clinical development pattern typical for centrally acting neuromodulators that target neurotransmitter systems (e.g., nicotinic, serotonergic) rather than plaque/tau biology. The P50 sensory\u2011gating paradigm used in the schizophrenia study is a translational biomarker most commonly linked to the \u03b17 nicotinic acetylcholine receptor and other neurotransmitter receptor modulation, supporting a neurotransmitter\u2011receptor hypothesis for a cognition\u2011directed small molecule. \ue200cite\ue202turn0search1\ue202turn0search3\ue202turn1search1\ue201",
        "Act: Key evidence from public registries shows multiple phase\u20111 entries for NSA\u2011789 (Alzheimer\u2019s multiple\u2011dose safety/PK/PD; schizophrenia P50 studies), but none of the public records specify a molecular target or class for NSA\u2011789. Because the available information points to a small\u2011molecule cognitive/neuromodulatory program (and the P50 link suggests receptor modulation), the most specific CADRO match is D) Neurotransmitter Receptors. Evidence: registry entries for the Alzheimer\u2019s and schizophrenia studies (NSA\u2011789) and the connection between P50 gating and \u03b17 nAChR. \ue200cite\ue202turn0search1\ue202turn0search3\ue202turn1search0\ue201",
        "Reflect: Classification caveats \u2014 the sponsor did not publicly disclose NSA\u2011789\u2019s molecular target in accessible registries or publications, so the D) Neurotransmitter Receptors assignment is an informed classification based on the drug\u2019s development context (cognitive enhancer, P50 testing) and the well\u2011established link between P50 and nicotinic/other neurotransmitter receptors. If definitive mechanistic data (e.g., company disclosure, patent, or peer\u2011reviewed pharmacology) become available showing a different pathway (inflammation, synaptic plasticity via non\u2011receptor mechanism, etc.), the CADRO assignment should be updated. Current public records do not permit a more specific receptor assignment. \ue200cite\ue202turn0search1\ue202turn0search7\ue201",
        "Web search sources (selected): 1) Registry entry for the multiple\u2011dose Alzheimer's NSA\u2011789 study (phase 1; safety/PK/PD). \ue200cite\ue202turn0search1\ue201 2) Registry entry for an NSA\u2011789 P50 auditory gating study in schizophrenia (phase 1; single\u2011dose P50 endpoint). \ue200cite\ue202turn0search3\ue201 3) Additional registry listings/summary for NSA\u2011789 schizophrenia multiple\u2011dose study (sponsor Pfizer/Wyeth; withdrawn/completed statuses). \ue200cite\ue202turn0search7\ue202turn0search9\ue201 4) Reviews and primary literature linking P50 auditory sensory\u2011gating deficits to the alpha\u20117 nicotinic acetylcholine receptor (background supporting the receptor\u2011modulation inference). \ue200cite\ue202turn1search1\ue202turn1search0\ue201 5) Note: searches and registry records did not reveal a public molecular target or company disclosure for NSA\u2011789 (hence inference rather than explicit target assignment). \ue200cite\ue202turn0search1\ue202turn0search7\ue201"
    ]
}